The Venture Capital Podcast with Fexingo · 2026-07-21 · 9 min
Colossal Biosciences is reportedly raising at a $20B to $30B valuation. Lucas and Luna break down the venture logic behind de-extinction: the science, the spinouts in gene editing and synthetic biology, and the parallels to longevity biotech. They examine whether Colossal's valuation is backed by real platform potential or hype, referencing the latest headlines and the broader VC appetite for frontier tech. The episode also touches on how VCs underwrite risk when the product is resurrecting the woolly mammoth. #DeExtinction #ColossalBiosciences #VentureCapital #StartupInvesting #GeneEditing #SyntheticBiology #LongevityBiotech #Biotech #Valuation #FrontierTech #Science #Business #Technology #FexingoBusiness #BusinessPodcast #VCPodcast #TermSheets #Startup Keep every episode free: buymeacoffee.com/fexingo
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
The Race to Build the Next Trillion-Dollar AI Chip CompanyTechSurge: Deep Tech Podcast · on Venture capital90 / 100
Bayt’s Rabea Ataya on 26 Years of Building and Why the Old MENA Startup Playbook No Longer WorksFWDstart · on Venture capital86 / 100
The Best of Series Six: The Professional Investment PodcastThe Professional Investment Podcast · on Venture capital81 / 100
He Made It To The NFL. Now He Wants To Prove Himself All Over Again.Catalyst by Camber Creek · on Venture capital74 / 100
Edward Robson - Capital Allocation in TechnologyCloud Returns · on Venture capital68 / 100
Tesla’s Roadster, Car Week Takes, Unwell Beverages Shuts Down | Diet TBPNTBPN · on Venture capital52 / 100
How VCs Are Pricing Startup Burn Rate in 202652 / 100Why VCs Are Underwriting Startup Supply Chain ResilienceHow VCs Are Pricing Startup Exits in 2026How VCs Are Valuing Startup Community in 2026How VCs Are Pricing Startup Adaptability in 2026